SCHEMBL29400616

SCHEMBL29400616

NCc1cccc(-c2ccccc2)c1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.70
LOXL2 Q9Y4K0 1/20 0.67
AGXT P21549 1/20 0.61
CFD P00746 4/20 0.56
AOC3 Q16853 3/20 0.53
HRH3 Q9Y5N1 1/20 0.52
PNMT P11086 1/20 0.52
ENPP2 Q13822 1/20 0.52
CSNK2A1 P68400 2/20 0.52
MAOA P21397 1/20 0.50
PLG P00747 1/20 0.50
PLAU P00749 1/20 0.50
F11 P03951 1/20 0.50
KLKB1 P03952 1/20 0.50
F7 P08709 1/20 0.50
TPSB2 P20231 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43554 1.00 TAAR1 (0.70) TAAR1LOXL2AGXTCFDAOC3
Hydrochloric Acid SCHEMBL29793666 0.98 TAAR1 (0.67) TAAR1LOXL2AGXTCFDAOC3
Hydrochloric Acid SCHEMBL1237399 0.98 TAAR1 (0.67) TAAR1LOXL2AGXTCFDAOC3
Bromide SCHEMBL1856525 0.98 TAAR1 (0.67) TAAR1LOXL2AGXTCFDAOC3
SCHEMBL28247640 0.98 TAAR1 (0.74) TAAR1LOXL2AGXTCFDAOC3
SCHEMBL27799749 0.98 TAAR1 (0.67) TAAR1LOXL2AGXTCFDAOC3
SCHEMBL3791745 0.93 LOXL2 (0.60) TAAR1LOXL2AGXTCFDHRH3
SCHEMBL3794460 0.91 TAAR1 (0.70) TAAR1LOXL2AGXTCFDHRH3
Benzylamine SCHEMBL11416949 0.90 LOXL2 (0.74) TAAR1LOXL2AGXTCFDAOC3
Biphenyl SCHEMBL27410798 0.90 TAAR1 (0.84) TAAR1LOXL2AGXTHRH3PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025213277-A1 N1-(3,4-DICHLOROPHENYL)MALEAMIDE DERIVATIVES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY DISORDERS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2025-10-16 WO disclosed
WO-2025076476-A2 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-10 WO disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 WO disclosed
CN-119212727-A Targeted bifunctional degradants 耶鲁大学 2024-12-27 CN disclosed
CN-117003776-A Boric acid proteasome inhibitor and application thereof 科辉智药生物科技(深圳)有限公司 2023-11-07 CN disclosed
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
CN-115315272-A Targeting difunctional degradation agent 耶鲁大学 2022-11-08 CN disclosed
EP-4041262-A1 TARGETED BIFUNCTIONAL DEGRADERS Yale University (US) 2022-08-17 EP disclosed
CN-108779042-B Ruthenium and osmium monocarbonyl catalysts 乌迪内大学 2022-07-19 CN disclosed
CN-114127050-A Benzopyran and imidazole derivatives useful for stabilizing amyloidogenic immunoglobulin light chains 斯克利普斯研究所 2022-03-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A TAAR1 116/4885LOXL2 1549/4885AGXT 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.